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ABSTRACT
Aim: To identify all cases of Neurofibromatosis type 1 in Northern Ireland under 16 years of age, document age, modes of 
presentation and any complications that occurred.
Methods: All cases of Neurofibromatosis type 1 in children less than 16 years of age were identified from the records in the 
Department of Medical Genetics. From the records and by direct contact with the patient’s parents the relevant clinical information 
was obtained.
Results: Seventy-five children aged sixteen years or less were identified (prevalence of 17.6 per 100,000 (1 in 5681) of the 
population under 16 years of age). 45 (57%) had an affected first degree relative and 32 (43%) had no family history.  54 (72%) 
had at least one complication, 18 (24%) had 2; 9 (12%) had 3 and 3 (4%) had 4 complications. The most common complication 
was learning difficulties, which was seen in 37 (49.3%) cases. 11 (14.7%) patients had a malignancy; of whom 5 (6.7%) had an 
optic glioma (2 identified after diagnosis) and 3 (4%) had a CNS malignancy.
Conclusion: Children with NF1 should be seen yearly by a health professional or team until after puberty and have a thorough 
clinical examination. The minimum prevalence is 1 in 5681 (17.6 per 100,000). We suggest a checklist is used to review nine 
important features; height, weight, head circumference, examination of the skin, blood pressure, ophthalmology examination 
(includes visual fields), examination of the spine, and for early / late puberty and consider referral to educational psychology. 
Educational authorities should identify all individuals with NF1 as they are at high risk of developing learning difficulties.
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INTRODUCTION
Neurofibromatosis  type  1  (NF1)  is  an  autosomal  dominant 
condition, which can cause growths, either on peripheral nerves 
or in the central nervous system, as well as multiple café au lait 
spots on the skin (figure 1). The condition is one of the most 
common genetic conditions; it occurs in around 1 in 4000 of the 
population and is noted for its variation of clinical expression1,2. 
It is associated with a significant reduction in life expectancy3. 
The gene for NF1 was localised to the long arm of chromosome 
17 in 19874. Neurofibromatosis type 1 occurs in every racial and 
ethnic group and affects both sexes equally. 
The diagnosis of NF1 can be made using the National Institutes 
of Health (NIH) diagnostic criteria5 (Table I). NF1 is associated 
with many other clinical features that can occur at all ages. 
Morbidity, due to complications of NF1, occurs mainly in adults 
but occasionally in children. NF1 can have an adverse effect 
on the child’s life. In this study, the population of individuals 
less than 16 years of age with NF1 in Northern Ireland was 
identified and the main causes of morbidity recorded.
METHODS
Northern  Ireland  has  well  developed  paediatric,  childhood 
dermatology and neurology services that liaise closely with 
Medical Genetics. Virtually all patients with NF1 in Northern 
Ireland (population 1.68 million, of whom 425,250 are aged 
under 16 years4) are referred to the Department of Medical 
Genetics in Belfast City Hospital for genetic counselling. A 
register of all cases of NF1 has been maintained since 1990. 
From the register, all patients under 16 years of age who were 
diagnosed as having NF1 were identified and the diagnosis 
verified  using  the  diagnostic  criteria  (Table  I).  From  the 
medical records, the presenting symptom of NF1 and all the 
relevant clinical signs and symptoms were documented. The 
parents of each patient were contacted and information was 
obtained on the child’s behaviour and school performance. Any 
complications that required medical or educational intervention 
and were present on the prevalence day were recorded. Learning 
difficulties were said to be present if the child had a statement 
of educational needs, or was placed in special schooling.
RESULTS
Seventy-five children aged sixteen years or less were identified. 
This gives a prevalence of 17.6 per 100,000 (1 in 5681) of the © The Ulster Medical Society, 2008.
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population under 16 years of age.  Figure 2 shows the incidence 
of NF1 in Northern Ireland from 1997-2002 and shows the 
number of cases that were the result of new mutations. Of the 
75 cases, 38 were male and 37 female. The mean age was 9.3 
years (range 0.9 - 16.8 years).
The age of diagnosis ranged from 3 months to 15.5 years (mean 
4.6 years). Some children were diagnosed early as there was a 
family history and these children were kept under review. 45 
(57%) had an affected first degree relative and 32 (43%) had 
no family history. Features seen are documented in Table II, 
and their frequency at diagnosis in figure 1. Café au lait spots 
were found in most of the 75 cases, a significant number had 
freckling in the axilla or the groin, 15 had neurofibromas and 
a  small  number  had  optic  gliomas,  Lisch  nodules  or  bone 
lesions.  In  our  cohort,  99  complications  were  documented 
in the 75 children. Fifty-four children (72%) had at least one 
complication. The types of complications and their frequency 
are documented in Table III and the majority occurred before 
10 years of age.  
DISCUSSION
In Northern Ireland, most cases of NF1 are referred to the 
specialist clinic for neurofibromatosis in the Department of 
Medical Genetics. Northern Ireland has a stable population 
with negligible patient drift to Great Britain or the Republic of 
Ireland. Together with the well developed and multiple referral 
and ascertainment routes, we believe, therefore, that this study 
shows a rigorous attempt at as complete ascertainment that is 
possible and allows calculation of a fairly accurate minimum 
prevalence figure. In the specialist clinic, the patient is offered 
genetic counselling and any complications of the condition are 
identified. At present the guidelines of the National Institute of 
Health are adhered to. A comprehensive clinical examination 
and  ocular  assessment  with  fundoscopy  is  performed.  By 
identifying the incidence and types of complications seen in 
cases that attend the clinic, these guidelines can be evaluated 
and recommendations can be made about any screening that 
should be undertaken.
We believe we have identified most of the significantly affected 
cases of NF1 in children less than 16 years of age in Northern 
Ireland. Although the prevalence rate of 17.6/100,000 is lower 
than a recent study in Germany which showed a prevalence of 
30/100,000 live births7, we believe our result is accurate and 
represents a minimum prevalence figure for childhood NF. The 
majority of other calculated prevalence figures include adults 
and it is likely that some adults with a mild skin phenotype or 
with complications such as phaeochromocytoma, which are 
recognised later in life, clearly would not be identified in our 
cohort. Figure 3 shows the incidence of NF1 during the period 
Ta b l e  I.
NIH Diagnostic criteria for type 1 neurofibromatosis. 
Two or more of the following criteria are 
required for diagnosis:
Six or more café-au-lait spots over 5 mm in  1. 
prepubertal individuals and over 15 mm in 
postpubertal individuals
Two or more neurofibromas of any type or one  2. 
plexiform neurofibroma.
Freckling in the axilla or groin. 3. 
Optic glioma. 4. 
Two or more Lisch nodules. 5. 
Presence of a distinct osseous lesion, sphenoid wing,  6. 
dysplasia or thinning of a long bone with or without 
pseudoarthrosis.
A first degree relative who meets the above criteria  7. 
for NF1.
Ta b l e  II.
Type and frequency of complications detected
Complication No. (%)  of children
Learning difficulties 37 (49.3)
Optic glioma 5 (6.7)
Epilepsy 3 (4)
Plexiform neurofibromas 7(9.3)
Pseudoarthrosis 4 (5.3)
Scoliosis 6 (8)
CNS malignancy 3 (4)
Non CNS malignancy 3 (4)
Short stature 5(6.7)
Large head 19(25.3)
Hypertension 1 (1.3)
Other non tumour 
complications
3 (4)
Number
of cases
Fig 1. Café-au-lait spots© The Ulster Medical Society, 2008.
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1997-2002 and shows that the number of new cases increased 
over that time. This is most likely due to better awareness about 
the condition, referrals, and clinic facilities, rather than a true 
increase in the number of cases. Undoubtedly the accuracy of 
the prevalence will improve with continued searching for cases 
and a repeat  ascertainment study in a few years time. 
A study in a large cohort of NF1 patients in the north west of 
England8 found that neurofibromas and Lisch nodules were 
more common than our results suggest. It is likely that the Lisch 
nodules were not looked for on diagnosis and because of the 
average young age of diagnosis (4.6 years) the neurofibromas 
had not developed.
This study shows that children with NF1 can develop a wide 
range of complications. These findings are useful in counselling 
families with NF1 - the most common complication is mild to 
moderate learning difficulties. All children with NF1 should 
identified by the education authorities in view of their high risk 
of developing learning difficulties. Other complications, like 
short stature, neurofibromas, large head and hypertension should 
be detected by a thorough clinical examination as recommended 
in the NIH guidelines (Table I). This also recommends regular 
ophthalmic examination for optic gliomas preferably by an 
ophthalmologist.  There  are 
no  screening  procedures 
for  epilepsy.  Riccardi1 
recommended that all patients 
with  NF1  should  have  an 
MRI  or  CT  scan  once, 
however this would not be an 
effective screening procedure 
and  in  this  study  the  low 
rate  of  CNS  malignancy 
would  suggest  that  regular 
radiological  investigations 
would  have  a  low  pick  up 
rate and subject the child to 
unnecessary investigations. 
Most of the children had either 
one or two complications but 
a small number suffered from 
multiple complications. This 
study did not include a more 
detailed look at the patterns 
of severity, unlike Huson et al9 who divided their patients into 
4 grades of severity. In their cohort of patients they found that 
the younger new mutations were more seriously affected than 
older new mutations. There was no difference in degrees of 
severity when they looked at parental status. The difference 
was attributed to ascertainment. No other study has offered 
any explanation to explain the different ways the NF1 gene is 
expressed in different patients. We suggest a checklist of nine 
features, which can be used by specialists or GP’s and will 
cover the majority of potential problems with NF1 (Table IV).   
A recent paper on guidelines for diagnosis 
and management of NF lists a useful onset 
age for many of the manifestations (table V), 
and this will alert paediatricians and other 
health professionals involved with children 
with a diagnosis of NF, on when to expect 
complications to arise11.
CONCLUSIONS
In this study of individuals under 16 years of 
age with NF1 we believe we achieved nearly 
total  ascertainment  in  Northern  Ireland 
and calculated a minimum prevalence rate 
of 1 in 5681 children under the age of 16 
years. This group of patients suffered a wide 
variety  of  complications. After  examining 
the frequency of complications we believe 
Ta b l e  III.
Frequency of children with one or more complication
Number of complications Number (%) of children
1 24 (32)
2 18 (24)
3 9 (12)
4 3 (4)
Total no. of complications  99
Fig 2. Frequency of major features found at diagnosis
Features as %. (Café au lait 91%; axillary freckling 41%; groin freckling 43%; neurofibromas 20%; optic 
glioma 4%; Lisch nodules 6%; osseous lesions 4%)
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Ta b l e  IV .
Suggested check list for yearly examination on patients with 
Neurofibromatosis type 1
Height
Weight
Head Circumference
Examination of skin
Blood pressure
Eye examination (includes visual fields)
Examination of spine
Examination for early / late puberty
Consider referral to Educational psychology
that the NIH guidelines are appropriate for detecting these 
complications. 
A study into the management of children with NF1 at a London 
teaching hospital10 found that there was a need amongst health-
care professionals for evidence-based guidelines. Our study 
provides an almost complete ascertainment of NF1 cases in 
a geographical area and provides a sound evidence base for 
management of NF1 in children.  
The authors have no conflict of interest.
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